Diabetic neuropathy: Past, present, and future

Abstract

Background: A sedentary lifestyle and an unhealthy diet have considerably increased the incidence of diabetes mellitus worldwide in recent decades, which has generated a high rate of associated chronic complications.

Methods: A narrative review was performed in MEDLINE, EMBASES and SciELO databases, including 162 articles.

Results: Diabetic neuropathy (DN) is the most common of these complications, mainly producing two types of involvement: sensorimotor neuropathy, whose most common form is symmetric distal polyneuropathy, and autonomic neuropathies, affecting the cardiovascular, gastrointestinal, and urogenital system. Although hyperglycemia is the main metabolic alteration involved in its genesis, the presents of obesity, dyslipidemia, arterial hypertension, and smoking, play an additional role in its appearance. In the pathophysiology, three main phenomena stand out: oxidative stress, the formation of advanced glycosylation end-products, and microvasculature damage. Diagnosis is clinical, and it is recommended to use a 10 g monofilament and a 128 Hz tuning fork as screening tools. Glycemic control and non-pharmacological interventions constitute the mainstay of DN treatment, although there are currently investigations in antioxidant therapies, in addition to pain management.

Conclusions: Diabetes mellitus causes damage to peripheral nerves, being the most common form of this, distal symmetric polyneuropathy. Control of glycemia and comorbidities contribute to prevent, postpone, and reduce its severity. Pharmacological interventions are intended to relieve pain.

Keywords: Diabetic Neuropathy, Diabetes Mellitus, Complication, Treatment, Glycemic Control, HbA1c

Citation:

From the ancient age in which observations on DN began until the present, there has been notable progress in the description of this pathology and the understanding of its underlying pathological mechanisms and treatments. Based on Skljarevski (1) and Boulton (2) Figure 1 depicts diabetic neuropathy historically, up to the present. Last decades, the acquisition of inadequate lifestyles has caused a large increase worldwide in components of the metabolic syndrome, including diabetes mellitus (DM) (3–5). The combination of genetic susceptibility and other factors such as a sedentary lifestyle and overeating are responsible for the appearance of DM. Prevention of the development of DM and its complications is essential to reduce the high morbidity and mortality it causes (4, 6, 7). Neuropathy as a complication of DM is associated with large social and health costs, in addition to a decrease in the quality of life (8–11). About half of the cases of neuropathy are secondary to DM (12). Diabetic neuropathy (DN) affects 30-50% of people with DM. The prevalence of DN in newly diagnosed diabetics is 8%, reaching more than 50% in those with long-standing DM (10, 13–16).
It is interesting that, although the incidence of neuropathy in people with type 2 DM (T2DM) is higher than in those with type 1 DM (T1DM), its prevalence is similar, which is probably due to differences in age of onset and its pathophysiology (17–22). DM is the main risk factor involved in the genesis of neuropathy, and its main predictors are the duration of DM and hemoglobin A1C (HbA1c) levels (22). Several epidemiological studies have shown that obesity is the second most important risk factor for the development of DN (23–29). The other components of the metabolic syndrome (hypertriglyceridemia, hypertension, and low levels of high-density lipoproteins) are also associated with DN in patients with T2DM and in some patients with T1DM (24, 25, 30). Other risk factors involved are smoking, alcoholism, tall stature, and advanced age (31). The role of genetics in the development of DN is not yet fully understood, so more research is required for future applications (32). The goal of this review is to describe the pathophysiology, clinical manifestations, diagnosis, and treatment of DN, and mention the current advances and future perspectives on its management.

Methods
Search strategy: MEDLINE, EMBASE, and SciELO

Electronic databases were searched for completed studies of any design except case reports, case series, letters to the editor, and conference proceedings from database inception between 2005 and 2022. The Medical Subject Heading (MeSH) used was "diabetic neuropathies" and includes the following concepts: diabetic autonomic neuropathy, diabetic neuralgia, symmetric diabetic proximal motor neuropathy, asymmetric diabetic proximal motor neuropathy, diabetic asymmetric polyneuropathy, diabetic mononeuropathy, diabetic amyotrophy, and diabetic polyneuropathy.

Inclusion and exclusion criteria: Inclusion criteria were studies published in English or Spanish, involving patients of any age. Systematic reviews, clinical trials, prospective cohort studies, cross-sectional and retrospective studies, and narrative reviews related to the objective of this manuscript were included. The investigation was limited to articles related to human beings, so that exclusion criteria were non-human studies. Case reports, case series, letters to the editor and conference proceedings were also excluded.

Screening: Identified citations were exported to Endnote. A total of 16873 citations were identified; 2105 duplicates were removed; 14768 titles and abstracts were screened against eligibility criteria. No grey literature was included. 14607 titles were excluded at the title and abstract screen, 162 eligible full text papers met the inclusion criteria. This process is summarized in Figure 2 Data extraction and synthesis: Results from the included papers were extracted to a table and include physiopathology, diagnosis, management, and therapies under study.

Quality assessment: The quality of our narrative review was evaluated using the SANRA scale, which included the following items: explanation of the importance of the review,
Diabetic neuropathy. An update

This narrative review has the endorsement of the Ethics Committee of the Faculty of Medicine of the National University of Trujillo.

Figure 2. Flowchart of narrative review process

Results

Physiopathology

DN is a degenerative problem of the nervous system that mainly affects sensory and autonomic axons, and progressively, to a lesser degree, motor axons. The exact mechanism by which DM targets sensory neurons remains unknown. DN develops progressively and involves the retraction and death of terminal sensory axons in the periphery, with relative preservation of the soma. Initially, the longest sensory axons are damaged, so the manifestations are first distal, developing to proximal. For this reason, DN is considered to be a length-dependent neuropathy (34). Chronic hyperglycemia causes damage to the Schwann cells, leading to demyelination in the most severe cases of DN. Given the interaction and mutual support between the axons and the Schwann cells, the damage of the latter would also lead to various alterations in the axons (35, 36).

Role of hyperglycemia and hyperlipidemia

The difference in the way of energy production in the peripheral nervous system of people with DM is the basis for understanding the pathogenesis of DN. When long-chain fatty acids are transported to Schwann cells and their axons in the dorsal root ganglia (DRG) to undergo β-oxidation, one molecule of acetyl-CoA is formed in each cycle, and it enters the tricarboxylic acid cycle for the formation of reduced nicotinamide adenine dinucleotide (NADH) and reduced flavin adenine dinucleotide (FADH2). DM has an overload of substrates that saturate the transport system, converting acetyl-CoA molecules into acylcarnitine. Accumulated acylcarnitine which is toxic to the Schwann cells and DRG neurons, is released from Schwann cells and can induce axonal degeneration, by mitochondrial dysfunction and maladaptation to stress, adding the nervous system injury (37, 38).

NADH and FADH2 enter the mitochondria by complexes I-IV to produce ATP through oxidative phosphorylation. This process generates reactive oxygen species (ROS) as by-products, but in small quantities, which are easily neutralized by cellular antioxidants such as superoxide dismutase, glutathione, and catalase (39, 40). Excessive substrate in DM leads to oxidative phosphorylation failure, decreased ATP production, and increased ROS levels, producing mitochondrial failure and metabolic and oxidative damage to Schwann cells and neurons. Of the DRGs (41–43).
Dysfunctional mitochondria do not produce enough energy and lose their normal capacity for transit through the axons, worsening axonal disruption and damage (44). These alternate routes to process the excess of glucose, as the polyol pathway and the hexosamine pathway, produce an excess of free fatty acids catabolized by β-oxidation causing damage to Schwann cells, through ROS and inflammation produced by the activation of macrophages and subsequent production of cytokines and chemokines. (45–47) Additionally, hyperglycemia leads to the glycation of structural and functional proteins, generating advanced glycation end-products (APGPs), which alter or decrease protein function and interact with specific PFGA receptors, modifying gene expression and intracellular signaling. (34) They also promote the release of pro-inflammatory molecules and free radicals. (48) Furthermore, in neurons, excess cholesterol is oxidized to oxysterols, which cause tissue damage (40, 49–51). Plasma lipoproteins, mainly low-density lipoproteins (LDL), are oxidized by ROS and bind to oxidized LDL receptor 1 (LOX1), toll-like receptor 4 (TLR4) and PFGA (52–54). The binding of oxidized LDL to these receptors activates a series of signaling cascades, including the activation of caspase 3 and the degradation of nuclear DNA, producing additional inflammation and the accumulation of ROS, thus contributing to progression of neuropathy (54, 55). Sphingolipid metabolism in people with T2DM is also altered, resulting in the formation of atypical deoxysphingolipids, which are toxic to neurons and pancreatic beta cells (56, 57). The level of deoxysphingolipids not only is elevated in people with metabolic syndrome or T1DM but much more in those with T2DM. Of the latter, those with DN present the highest levels (58, 59). Excess of glucose and fatty acids and their relation to inflammation and tissue damage.

**Figure 3. Relationship of the glucose and fatty acid metabolism with DN.** (a) The normal metabolism of glucose and fatty acids, which, through a series of complementary mechanisms, end in the production of ATP. (b) The effects of DM on the normal metabolism of glucose and fatty acids, overloading the transport system and causing failure of oxidative phosphorylation. (c) The effects of an excess of glucose and fatty acids and their relation to inflammation and tissue damage. (34)
Role of dysfunction in the microcirculation

Poor blood supply to peripheral nerves is another possible pathological mechanism involved in DN. Microcirculatory dysfunction is associated with peripheral nerve dysfunction, leading to further nerve damage. DM patients exhibit higher capillary density in the endometrium, probably influenced by DM-induced nerve ischemia (60). The basement membrane of blood vessels undergoes thickening and is also associated with nerve damage (61). DM also decreases vascular formation mediators such as insulin-like growth factors, vascular endothelial growth factor (VEGF), nerve growth factor (NGF), and angiopeptins (62).

Role of insulin resistance

Normally, insulin acts as a growth factor for sensory neurons, allowing the growth of neuronal processes. Insulin receptors are expressed in the sensory neurons of the DRGs and axons, especially in the nodes of Ranvier (63, 64). Glycemic control with insulin has little effect on neuropathy in patients with T2DM given the insulin resistance developed by the neurons, similar to that of the muscle and adipose tissue. In contrast, in T1DM, the benefit on neuropathy is notorious (65, 66).

Mechanisms of neuropathic pain

Nearly half of DN patients develop neuropathic pain, frequently manifested as a spontaneous burning pain in the feet (67). Alloodynia, paresthesia, and loss of sensitivity have also been reported. The presence or absence of neuropathic pain is probably due to a complex interaction of genetic factors, somatosensory circuitry, and psychological factors (68).

Being female increases the risk of painful DN. The severity of the neuropathy, poor glycemic control, renal dysfunction, and a higher body mass index are risk factors for neuropathic pain and are associated with neuropathy progression (69, 70).

Damaged sensory neurons present hyperexcitability, and generate spontaneous activity by action potentials in the absence of a stimulus and an altered response. This aberrant activity is what initiates and allows the continuation of neuropathic pain (71, 72). The pathogenesis of neuropathic pain also involves genetic variations of ion channels and alterations in their expression, trafficking, and post-translational modifications, such as an increased expression of the Nav1.8 subunit of the channel, voltage-gated sodium in sensory neurons, which contributes to hyperexcitability of DRG neurons (73-75).

In addition, hyperglycemia increases the expression of glyoxal, a reactive metabolite that forms PFGA by modifying ion channel cellular proteins, altering their function (76,77). In DN, there is an increased influx of spontaneously active nociceptors into the spinal cord, which enhances synaptic transmission, further amplifying nociceptive signaling in a process called central sensitization. Microglia exhibit a proinflammatory phenotype, although the exact form is unknown. These cells can release factors, such as brain-derived neurotrophic factor, that amplify nociceptive synaptic signaling within the spinal cord and contribute to mechanical pain-related hypersensitivity (78,79).

Sensory-motor neuropathy

Several clinical syndromes of DN have been described, very different from each other, although often coexisting. Sensorimotor neuropathy includes distal sensory polyneuropathy, acute mononeuropathies, multiple mononeuropathies, and radiculopathies (80). Distal sensory polyneuropathy is the most frequent form and in more than 50% of cases, it generates symptoms like burning pain, electrical or stabbing sensations, paresthesia, and hyperesthesia, which are usually worse at night and reduce the ability to perform daily activities (81, 82).

In the examination of the lower extremities, loss of sensitivity to vibration, pressure pain, and temperature is usually found, as well as decreased or absent osteotendinous reflexes. When there is muscle weakness, it is usually mild (81, 83). Some patients develop early neuropathy, not necessarily associated with the use of insulin or oral hypoglycemic agents, and manifest only pain and paresthesia, which corresponds to another entity called insulin neuritis (84). In order of frequency, the most common acute mononeuropathies are paralysis of the oculomotor nerve and those of the trochlear and facial nerves (84). They are usually associated with nerve ischemia and generally appear during a transition period in DM, such as after an episode of hyperglycemia or hypoglycemia, when the insulin therapy regimen is started or adjusted, or when there is rapid weight loss (83).

Multiple mononeuropathies are unilateral or asymmetric painful neuropathies that start abruptly in one nerve and then sequentially or irregularly affect other nerves (80). These radicular-plexopathies present sub-acutely with pain followed by weakness, and mainly affect older people with mild or undiagnosed DM. The main forms are cervical, thoracic, and lumbosacral radicular-plexopathy, and they can present
separately or simultaneously (85). Of these, lumbosacral radicular-plexopathy is the one that produces the greatest morbidity, with intense pain that begins in the waist or hips and extends to the thigh and knee on one side, associated with kneeling and might be more intense at night. Pain is the main discomfort at the beginning, but gradually weakness and atrophy become the biggest problem, mainly affecting the pelvic girdle and the thighs, and progressively it may spread more distally. Due to the above, it is also known as diabetic amyotrophy (83–85).

**Autonomic neuropathies**

Autonomic neuropathies can affect cholinergic, adrenergic, and peptidergic fibers, and can be sub-clinically detected with tests or become evident with signs and symptoms (86).

Cardiovascular autonomic neuropathy arises as a result of the interaction between glycemic control, duration of DM, age-related neuronal wear, and blood pressure (86). Its manifestations include altered heart rate variability, tachycardia at rest, exercise intolerance, blood pressure dysregulation, and orthostatic hypotension (87, 88). Although symptoms appear years after DM onset, subclinical involvement can be detected as early as 1 year after T2DM diagnosis and 2 years after T1DM diagnosis. This form of neuropathy is associated with the highest morbidity and mortality (88, 89).

Gastrointestinal autonomic neuropathy is usually a diagnosis of exclusion due to the difficulty in evaluating gastrointestinal function in humans. It affects up to 75% of people with DM (87, 88). It produces nausea, bloating, abdominal pain, diarrhea, constipation, and delayed gastric emptying, altering the absorption of medications, hindering glycemic control, and producing malnutrition and a poor quality of life (87, 90). Another type of autonomic neuropathy is erectile dysfunction, which affects more than 50% of men with DM and is caused by neuropathy and endothelial dysfunction. Given its close relationship with endothelial dysfunction, erectile dysfunction is an early marker of cardiovascular risk (91-93). Bladder dysfunction occurs due to involvement of autonomic and sensory nerve fibers (94, 95). The first thing that is altered is the sensitivity in the bladder, producing delayed urinary reflexes, increased bladder capacity, and urinary retention (88, 95). This can happen asymptotically, becoming the dysfunction evident when a urinary tract infection occurs secondary to the increase in residual urine volume (96). Besides, autonomic neuropathy initially produces loss of thermoregulatory sweating in the extremities and anterior abdomen, culminating in global anhidrosis. In some cases, it causes hyperhidrosis (97).

**Diagnosis**

DN presents in a heterogeneous manner and on many occasions without a correlation with glyceria figures, possibly, being it not impossible to go together with renal DM complications, which lowers the blood sugar level. So, defining it accurately and, even more, classifying it is sometimes controversial. For a better understanding of its manifestations, it is usually classified into two groups, being generalized symmetrical polyneuropathy which includes the acute sensory, chronic sensory-motor, and autonomic form, and the focal and multifocal neuropathy. The last group includes the list of cranial, truncal, focalized in one extremity, proximal motor or neuropathy amyotrophic, and chronic inflammatory demyelinating polyneuropathy forms (80, 81, 98). The diagnosis of DN is clinical, based on an adequate anamnesis and physical examination, restricting objective confirmatory tests mainly to the field of research or in the case of atypical clinical presentations (10,88). The heterogeneous presentations like tingling, together with lancinating pain, accompanied by weakness and instability in the extremities, from distal to proximal onset, occur in most patients and are the necessary elements for diagnosis (10, 80, 88). The signs and symptoms (99) together with the systemic manifestations (81) are summarized in Table 1, which are easy to identify in a clinical evaluation.

The great variety of signs and symptoms can be organized into a series of scales that can help us to formalize the diagnosis. Despite the passage of time, the Toronto Clinical Neuropathy Score is still used due to its easy application and high reproducibility in any medium. This scale considers the symptoms of foot pain, numbness, tingling, weakness, ataxia, and upper limb symptoms, as well as knee and ankle reflexes, finishing with the sensory tests using a monofilament, temperature perception, vibration, position, and light touch. It offers a total score from 0 to 19, where a higher score reflects greater nerve damage (100,101). If a patient with pain, paresthesia, and/or weakness complains of atypical sub-acute or acutely characteristics, or presents a heterogeneous distribution, an objective diagnostic laboratory test is necessary (99,102) to rule out vitamin B12 deficiency, especially if the patient is a long-term metformin user (103), as well as thyroid function control, even screening for autoimmune diseases. Rarely, a biopsy of the sural or radial nerve is necessary (10, 98, 104).
Table 1. Common systemic signs and symptoms of Diabetic neuropathy

<table>
<thead>
<tr>
<th>Symptom</th>
<th>Cardiovascular</th>
<th>Gastrointestinal</th>
<th>Genitourinary</th>
<th>Nervous</th>
<th>Skin and appendages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptom</td>
<td>Intolerance to exercise, weakness, fatigue</td>
<td>Nausea, early satiety, abdominal pain</td>
<td>Erectile dysfunction, vaginal dryness</td>
<td>Paresthesia, hyperalgesia, allodynia</td>
<td>Intolerance to heat or cold, blurred vision</td>
</tr>
<tr>
<td>Signs</td>
<td>Postural syncope, hypotension.</td>
<td>Diarrhea, constipation.</td>
<td>Urinary retention, urinary incontinence.</td>
<td>Reduced sensation to painful and non-painful stimuli.</td>
<td>Anhidrosis, hyperhidrosis, inability to adapt to ambient light.</td>
</tr>
</tbody>
</table>

Differential diagnosis
As has been noted, there are different forms of presentation of DN, with distal-onset generalized symmetric polyneuropathy being the most frequent form. However, it must be taken into account that not all diabetic patients have neuropathy secondary to DM. In fact, in approximately 1 in 10 diabetics with neuropathy, DM is not the responsible entity, but rather some other cause is involved (34,105). That is why it is necessary to assess other etiologies that can generate neuropathy such as alcohol abuse, genetic alterations, neoplasms, medications like chemotherapy and HIV treatments, and amyloidosis. An adequate clinical history is essential to know what type of patient should have a more exhaustive search for another cause. (10.34)

Screening
All screening tests must be easy and fast to apply, and their results reliable, so the arsenal of tests used for DN screening is very small. The 10-gram monofilament together with the 128 Hz tuning fork have similar screening power, compared with other more expensive and difficult-to-apply methods to discriminate DN (10,34,105–107). The American Diabetes Association, as well as the American Academy of Neurology, recommend screening for ND at diagnosis and annually for patients with T2DM, and 5 years after diagnosis and annually thereafter for patients with T1DM (10,105).

Prevention
In both T1DM and T2DM, the base harm is hyperglycemia, so evidently, glycemic control is the base of DN prevention, however, the outcome does not seem to be the same in the different types of DM, since the incidence decreases very slightly in patients with T2DM compared to patients with T1DM, making us know that the pathophysiological mechanism of each type of DM plays a crucial role in this complication (107,108). In not many years we will be able to have adequate studies at hand to take a position on other types of interventions such as metabolic surgeries, which help in the remission of DM2, but we still cannot adequately distinguish what role they play in complications such as DN.

Management
The management of DN includes 4 main strategies: glycemic control, intervention in diet and lifestyles, therapies aimed at the pathogenesis of the disease, and symptomatic
relief of neuropathic pain (109). The latter being perhaps the main objective sought by the patient but which the clinician must always consider within the global management mentioned.

**Glycemic control**

The DCCT study showed that intensive glycemic control can delay the onset of DN in patients with T1DM. After 6.5 years of follow-up, the intensive glycemic control group with a mean HbA1c of 7.4% had an increase in frequency of DN from 7% to 9% compared to the conventional glycemic control group with a mean HbA1c of 9.1% what presented an increase from 5% to 17% in the frequency of DN (110). Glycemic control is less effective in preventing the progression of DN in patients with DM2. The UKPDS study did not show a significant difference in the frequency of DN between the conventional and intensive glycemic control groups with sulfonylureas or insulin (111). These data should not lead us to suppose that glycemic control is less relevant in T2DM as it affects also other organs and physiological pathways, such as the nervous system, and must be controlled (109, 112). The previously mentioned studies involve a large international population and assessed the intensity of glycemic control by a trimestral HbA1c, which proved to be an important tool in disease management. The result of the HbA1c value has to be considered not to be completely adequate in patients with hemoglobin alterations, like in any anemia, iron deficiencies, chronic kidney disease, polycythemia, and related clinical conditions. In addition, the high glycemic variability that a patient with frequent dietary transgressions can present can only be distinguished in daily continuous glucose monitoring. This is why numerous studies have appeared in recent years that attempt to assess whether glycemic variability plays a role in the progression of complications, finding that it does play a role as an independent factor in the development and progression of DN in T1DM as well as T2DM; therefore, the use of continuous glycemic monitoring systems may become more relevant (113–116). *** The most recent studies have been summarized in Table 2.

*** References 117–123 are in Table 2.

**Diet and lifestyle**

Evaluating the impact of diet itself in the treatment of DN, we have not found strong evidence of direct benefit, however, it is deduced that an adequate diet that allows glycemic control should have a positive impact on the complications of DN, so on ND. Within the range of possibilities, the total vegetarian or vegan diet can have a beneficial effect on the symptomatic control of DN (124). Another option that has shown a benefit in the control of metabolic diseases is the Mediterranean diet, having as its main characteristic the high consumption of fats from vegetable oils and proteins from fish meat. This has not generated direct evidence so far in the improvement of DN symptoms, but in the progression of the disease and in inflammatory mechanisms that are related to the pain pathways, which can reduce symptoms this way (125-127). Very low-calorie diets, between 200-500 kcal/day, could have a beneficial effect by reducing insulin resistance and improving glycemic control figures, but given the possibility of an increase in ketone bodies, there is no clear picture(128). Nutrient deficiencies might be an additional risk in time. Obesity control and weight reduction to a normal MIC can improve the structure and function of peripheral nerves (129).

Metabolic surgery in DM to generate greater and faster weight loss is approved by health securities in some countries. Ketogenic diets and Dietary-Approaches-to-Stop-Hypertension (DASH) diets have only shown clear benefits in the management of arterial hypertension.

Mild to moderate-intense physical exercise can have a beneficial impact on neuropathic pain reduction and DN control (130) not only because of the control effect on hyperglycemia itself but also because it influences plasticity mechanisms that can improve symptoms (131).

**Disease-modifying therapies**

Two drugs that are approved for the treatment of DN in multiple countries, stand out: alpha-lipoic acid, which reduces oxidative stress, and benfotiamine, which inhibits the accumulation of PFGA (132,133).

Several randomized clinical trials have shown the efficacy and safety of alpha-lipoic acid 600 mg daily in reducing neuropathic symptoms, intravenously after 3 weeks and orally after 5 weeks of treatment (134–137). Benfotiamine is a pro-drug of thiamin (vitamin B1). The BENDIP (Benfotiamine in Diabetic Polyneuropathy) clinical trial showed a significant improvement in neuropathic symptoms after 6 weeks of treatment with a dose of 300 mg every 12 hours, which proved to be the optimal effective and safe dose (138).

More large-scale studies are needed before these drugs can be recommended in the clinical practice.
Table 2. Impact of the glycemic variability on Diabetic neuropathy

<table>
<thead>
<tr>
<th>Study</th>
<th>Populación and type</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oyibo SO et al. 2002.</td>
<td>Randomized clinical trial in 20 T1DM patients.</td>
<td>It was found that the mean glycemic variability was higher in painful DN, but without statistical significance.</td>
</tr>
<tr>
<td>Kwai NC et al. 2016.</td>
<td>Randomized clinical trial in 17 T1DM patients.</td>
<td>In patients with higher glycemic variability, greater neuronal excitability was found.</td>
</tr>
<tr>
<td>Akaza M et al. 2018.</td>
<td>Randomized clinical trials in 13 and 27 T1DM and T2DM patients, respectively.</td>
<td>Glycemic variability was independently associated with an increased risk of medial plantar neuropathy.</td>
</tr>
<tr>
<td>Dublin LB et al. 2020.</td>
<td>Randomized clinical trial in 159 T1DM patients.</td>
<td>The perception of vibrations measured in Hertz was evaluated, finding fewer vibrations in patients with better glycemic control.</td>
</tr>
<tr>
<td>Mizokami-Stout KR et al.</td>
<td>Retrospective cohort in 5936 T1DM patients.</td>
<td>A significant association of painful DN was found with those patients who presented acute diabetic complications during follow-up.</td>
</tr>
<tr>
<td>Feng ZQ et al. 2021.</td>
<td>Randomized clinical trial in 95 T1DM patients.</td>
<td>A significant correlation was found between time in the glycemic range and HbA1c-independent sudomotor dysfunction.</td>
</tr>
</tbody>
</table>

**Pain management**

Pain relief in patients with DN has been a great challenge and its adequate approach must take into account multiple factors. Despite the high prevalence of DN, only 40% of patients receive a treatment considered first or second line in the treatment of DN. A similar percentage does not receive any treatment (139). There are more than 30 drugs recommended for the treatment of DN, with different efficacy, safety, and level of evidence. Therapeutic efficacy is considered with a significant reduction in symptoms, approximately 50% on pain scales. But none of them has been shown to achieve complete pain relief. In clinical practice, two approaches to pain management stand out. The first focused on the DN phenotype and neuropathic pain and the second approach focused on the presence of comorbidities, including anxiety, depression, sleep disorders, chronic complications of DM, cardiovascular diseases, among others(140).

Two DN phenotypes have been described: a paresthesia-like pain phenotype and a paroxysmal pain phenotype. For the paresthesia-like pain phenotype, it is recommended to start treatment with duloxetine (141). While for the phenotype of pain with paroxysms, treatment with high doses of pregabalin is recommended (142). Both drugs are recognized as first-line drugs in DN. Regarding the approach according to comorbidities, the use of duloxetine is recommended in patients with depression. In patients with anxiety or sleep disorders, it is preferred to initiate treatment with pregabalin. In the absence of improvement, tricyclic antidepressants could be added as second-line therapy (133), always emphasizing to the patient that the symptomatic relief of pain is not instantaneous and that the dose should be titrated according to each patient and based on the doses accepted until now. The drugs are described in table 3 with the recommended dose, additionally, the time in weeks on average that it must have been administrated to show an effect (112). *** Finally, the treatment must be evaluated and valued by the patient, currently existing various scales such as the Diabetes Quality of Life (DQOL) or the Diabetes-Specific Quality of Life Scale (DSQOLS) (151), which attempt to assess objectively the improvement or deterioration in the quality of life (152).

*** References 143–150 are in Table 2.
Table 3. Drugs involved in the treatment of Diabetic neuropathy

<table>
<thead>
<tr>
<th>Drug</th>
<th>Intervention</th>
<th>Goal</th>
<th>Dose (mg/d)</th>
<th>Effect (weeks)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duloxetine</td>
<td>First-line Anti-depressive</td>
<td>SNRI</td>
<td>40-60</td>
<td>10-12</td>
</tr>
<tr>
<td>Pregabalin</td>
<td>First-line Anti-convulsant</td>
<td>α2-δ ligand</td>
<td>300-600</td>
<td>8-12</td>
</tr>
<tr>
<td>Alfa-lipoic acid</td>
<td>First-line Neuromodulator</td>
<td>NF-κB, ROS, TRPV1</td>
<td>600-1800</td>
<td>4-6</td>
</tr>
<tr>
<td>Benfotiamine</td>
<td>First-line Neuromodulator</td>
<td>Hexosamine pathway</td>
<td>100-300</td>
<td>4-6</td>
</tr>
<tr>
<td>Amitriptyline</td>
<td>Second-line Anti-depressant</td>
<td>SNRI</td>
<td>25-100</td>
<td>2-4</td>
</tr>
<tr>
<td>Valproic acid</td>
<td>Second-line Anticonvulsant</td>
<td>GABA</td>
<td>1000-1200</td>
<td>4-12</td>
</tr>
<tr>
<td>Gabapentin</td>
<td>Second-line Anti-convulsant</td>
<td>GABA</td>
<td>900-3600</td>
<td>4-6</td>
</tr>
<tr>
<td>Carbamazepine</td>
<td>Second-line</td>
<td>Sodium channels</td>
<td>400-800</td>
<td>8-12</td>
</tr>
</tbody>
</table>

GABA: gamma-aminobutyric acid; NF-κB: Nuclear factor kappa B; ROS: reactive oxygen species; SNRI: Serotonin–norepinephrine reuptake inhibitor; TRPV1: transient receptor potential vanilloid 1

Therapies under study

There is a lot of interest in therapeutic agents focused on other points within the pathophysiology of DN, which is why new drugs are under study (153,154). Desensitization of the temperature-sensitive transient receptor potential channel in nociceptive neurons has been proposed as an interesting therapeutic option considering the pain pathways, through the application of topical capsaicin, which is still only approved for the management of painful DN in feet (155). The use of low-voltage electrical current stimulation of the spinal cord with success in some studies is also under investigation (156,157).

Mutations in voltage-gated sodium channels such as Nav1.7 have been implicated in painful DN, and are the target of antagonists such as the drug Xenon402, which is useful in erythromelalgia and has the potential to be used in other types of neuropathic pain (158,159). The intrathecal administration of drugs such as morphine and ziconotide allows direct release into the cerebrospinal fluid, with fewer side effects than systemic administration; however, their use in DN has not been evaluated, and this could be complicated by the difficulty in healing of wounds that people with DM are prone to (160,161).

The benefit of topical application of O2 and CO2 nanobubbles for the treatment of DN symptoms is also being studied in more than 50% of patients with success so far (162). In conclusion, Diabetes mellitus causes damage to peripheral nerves, with a variety of clinical manifestations. The most common form is distal symmetric polyneuropathy. Control of glycemia, blood pressure, and other components of the metabolic syndrome contribute to prevent or postpone it, as in other cases, stopping the progression of this condition or in the worse cases, reducing its severity. Intervention in lifestyles such as an appropriate diet and exercise also provide benefits in its management.

Pharmacological interventions may be aimed at relieving pain, but there is considerable progress made in disease-modifying therapies. There are many aspects of this disease that are still being investigated to improve its prevention and treatment.

Acknowledgments

None to declare

Funding: None to declare

Conflict of Interests: None to declare

Authors’ contribution: Concepción-Zavaleta M and Quiroz-Aldave J designed the outline of this article review. Quiroz-Aldave J, Durand-Vásquez M, Gamarra -Osorio E, Suarez-Rojas J and Alcalá-Mendoza R were the main writers and performed literature review. Roseboom P, Concepción-Urteaga L, and Concepción-Zavaleta M were reviewers and prepared the manuscript. Roseboom P, Coronado-Arroyo J and Zavaleta-Gutiérrez F were translators and interpreters, and performed written contribution to the text body. All authors have read and approved the final manuscript.
References


103. Yang W, Cai X, Wu H, Ji L. Associations between metformin use and vitamin B12 levels, anemia, and


